Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 18, 2021 /PRNewswire/ — Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of a Phase 2 study of the company’s…


Continue Reading

HEDGE accordingly